Skip to main content
. 2020 Jan 28;116(12):1981–1994. doi: 10.1093/cvr/cvaa008

Figure 5.

Figure 5

Impact of LINC00961 transcript and SPAAR micropeptide overexpression in in vitro angiogenic assays. (A) Schematic representation of LINC00961 LV constructs with transcript length in base pairs (bp) and encoded peptide length in amino acids (aa). (B) qRT-PCR validation of the LV constructs overexpression in HUVECs using primers targeting the ORF sequence. Unpaired t-test, comparison test vs. LV-EMPTY (n = 4). (C) Representative western blot of SPAAR micropeptide and β-actin in HUVECs infected with the LV constructs. (D) Network formation assay comparing HUVECs transfected with LV constructs. Branch length assessed by Image J Angiogenesis plugin. Unpaired t-test vs. LV-EMPTY (n = 3). (E) Representative Phase contrast of network formation assay of HUVECs transfected with LV constructs. (F) Analysis of average barrier resistance, expressed as Rb [Ohm × cm2], across a 10 h time course (n = 4, one-way ANOVA). Scale bar =0.5 mm. On the graphs, *P < 0.05, **P < 0.01, ***P < 0.001.